Long-Term Study Examines ADHD Medication Safety
Researchers present new findings on the long-term impact of methylphenidate at the European College of Neuropsychopharmacology.
Updated on Oct. 28, 2026 in Autism
Live Poll
Do you feel confident in the long-term health safety of ADHD medications prescribed to children?
New observational study findings suggest that while ADHD medications like methylphenidate offer benefits in reducing learning gaps, they carry long-term cardiovascular and psychiatric risks. These results were presented to address limited evidence regarding the safety and tolerability of common ADHD treatments.
Why it matters
Understanding the longitudinal effects of ADHD medications is vital as usage rates have risen by nearly 10% annually across 64 countries since 2015. Clinicians rely on these data to balance the known improvements in academic performance against potential risks like cardiovascular disease and new-onset psychosis.
The ADDUCE study followed 1410 children and adolescents over 24 months, finding systolic blood pressure rose from 108 mm Hg to 113 mm Hg in the methylphenidate group. Longer cumulative use of ADHD medication is associated with a higher risk for cardiovascular disease.
The players
European College of Neuropsychopharmacology
This scientific association is dedicated to the development and dissemination of research in neuropsychopharmacology.
The details
Researchers found that while methylphenidate effectively inhibits dopamine and norepinephrine reuptake to assist 5%-7% of the youth population with ADHD, it showed no substantial effect on growth over two years. Separate studies noted that amphetamine use is linked to a 1.65 hazard ratio for new-onset psychosis compared to methylphenidate.
Timeline
Annual ADHD medication use rose by nearly 10% between 2015 and 2019.
Findings were presented on October 28, 2026, at the 39th Congress of the European College of Neuropsychopharmacology.
Health Landscape
These results extend the ADDUCE study by providing long-term clinical data that updates our understanding of ADHD medication safety profiles. The findings mark a departure from short-term efficacy studies by emphasizing the necessity of monitoring cumulative physiological risks in pediatric patients.
Patients and caregivers should be aware that while medication can help close learning gaps by approximately 12%, it requires ongoing monitoring for changes in blood pressure and heart rate. Parents should discuss the cardiovascular and psychiatric risk profiles of specific ADHD treatments with their healthcare providers.
The takeaway
These findings underscore the importance of weighing clear academic benefits against potential long-term physiological side effects when managing ADHD. Patients should prioritize regular clinical check-ups to monitor blood pressure and psychiatric health during long-term medication use.
Further reading
For broader context on neurodevelopmental conditions, visit the Autism section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you feel confident in the long-term health safety of ADHD medications prescribed to children?
